MCRB
MCRB
NASDAQ · Biotechnology

Seres Therapeutics Inc

$13.96
+0.56 (+4.18%)
As of Feb 8, 2:09 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 48.20M 47.44M 44.02M
Net Income 4.12M 5.52M 4.21M
EPS
Profit Margin 8.6% 11.6% 9.6%
Rev Growth -6.7% +12.6% +20.6%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 32.34M 29.85M 36.89M
Total Equity 67.43M 62.46M 70.73M
D/E Ratio 0.48 0.48 0.52
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 8.55M 8.75M 8.39M
Free Cash Flow 5.08M 3.59M 3.32M